Kyverna Therapeutics, Inc. financial data

Symbol
KYTX on Nasdaq
Location
Emeryville, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 659% % -43%
Debt-to-equity 18% % 31%
Return On Equity -78% % -52%
Return On Assets -66% % -74%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43,796,170 shares 1.4%
Common Stock, Shares, Outstanding 43,794,087 shares 1.5%
Weighted Average Number of Shares Outstanding, Basic 43,415,367 shares 0.6%
Weighted Average Number of Shares Outstanding, Diluted 43,415,367 shares 0.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $137,189,000 USD 43%
General and Administrative Expense $34,397,000 USD 28%
Operating Income (Loss) $171,586,000 USD -40%
Nonoperating Income (Expense) $10,594,000 USD -14%
Net Income (Loss) Attributable to Parent $160,992,000 USD -45%
Earnings Per Share, Basic -3 USD/shares 90%
Earnings Per Share, Diluted -3 USD/shares 90%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $34,164,000 USD -67%
Marketable Securities, Current $136,974,000 USD -37%
Cash, Cash Equivalents, and Short-term Investments $171,100,000 USD -47%
Assets, Current $174,925,000 USD -46%
Property, Plant and Equipment, Net $1,793,000 USD -43%
Operating Lease, Right-of-Use Asset $4,317,000 USD -40%
Other Assets, Noncurrent $5,358,000 USD 186%
Assets $187,156,000 USD -45%
Accounts Payable, Current $3,016,000 USD -70%
Liabilities, Current $33,871,000 USD 9.3%
Operating Lease, Liability, Noncurrent $1,331,000 USD -73%
Liabilities $35,210,000 USD -3.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax $29,000 USD -81%
Retained Earnings (Accumulated Deficit) $387,023,000 USD -71%
Stockholders' Equity Attributable to Parent $151,946,000 USD -50%
Liabilities and Equity $187,156,000 USD -45%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 490,000,000 shares 0%
Common Stock, Shares, Issued 43,794,087 shares 1.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $161,116,000 USD -46%
Lessee, Operating Lease, Liability, to be Paid $5,100,000 USD -43%
Property, Plant and Equipment, Gross $5,376,000 USD -17%
Operating Lease, Liability, Current $3,495,000 USD 16%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $8,760,000 USD 6.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%